AR083058A1 - Compuestos de estructura de imidazotriazinona - Google Patents

Compuestos de estructura de imidazotriazinona

Info

Publication number
AR083058A1
AR083058A1 ARP110103426A ARP110103426A AR083058A1 AR 083058 A1 AR083058 A1 AR 083058A1 AR P110103426 A ARP110103426 A AR P110103426A AR P110103426 A ARP110103426 A AR P110103426A AR 083058 A1 AR083058 A1 AR 083058A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
4alkyl
heterocycloalkyl
Prior art date
Application number
ARP110103426A
Other languages
English (en)
Original Assignee
Envivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Envivo Pharmaceuticals Inc filed Critical Envivo Pharmaceuticals Inc
Publication of AR083058A1 publication Critical patent/AR083058A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Son inhibidores de fosfodiesterasa 9. La presente provee, además, procesos, composiciones farmacéuticas, preparaciones farmacéuticas y uso farmacéutico de los compuestos en el tratamiento de enfermedades o trastornos asociados con PDE9 en mamíferos, incluyendo humanos.Reivindicación 1: Un compuesto de fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde X se selecciona de un enlace, C(O) o S(O)2; R1 se selecciona en forma independiente del grupo que consiste en H, alquilo C1-6, alcoxi C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, cicloalcoxi C3-7, heterocicloalquilo, heterocicloalquil alquilo C1-4 y heterocicloalquiloxi, cada uno de los cuales puede estar sustituido en forma adicional con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, -S(O)2alquilo C1-4, OH, -C(O)-alquilo C1-4, oxo, CN, alquilo C1-6, alcoxi C1-4, cicloalquilo C3-7, -C(O)NH-alquilo C1-4, -C(O)N[alquil C1-4-alquilo C1-4], alquil C1-4-C(O)-, alquilsulfonilo C1-4-, -S(O)2NH-alquilo C1-4, y -S(O)2N[alquil C1-4-alquilo C1-4]; R2 se selecciona en forma independiente del grupo que consiste en alquilo C1-6, cicloalquilo C3-10, cicloalquil C3-7-alquilo C1-4, heterocicloalquilo, heterocicloalquilalquilo C1-4, heteroarilo, heteroarilalquilo C1-4, fenilo restringido y fenilalquilo C1-4 restringido, cada uno de los cuales puede estar sustituido en forma adicional con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, -S(O)2alquilo C1-4, OH, -C(O)-alquilo C1-4, oxo, CN, alquilo C1-6, alcoxi C1-4, cicloalquilo C3-7, -C(O)NH-alquilo C1-4, -C(O)N[alquil C1-4-alquilo C1-4], alquil C1-4-C(O)-, alquilsulfonilo C1-4-, -S(O)2NH-alquilo C1-4, y -S(O)2N[alquil C1-4-alquilo C1-4]; y R3 se selecciona en forma independiente del grupo que consiste en alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, heterocicloalquilo, heterocicloalquilalquilo C1-4, heteroarilo, heteroarilalquilo C1-4, fenilo restringido y fenilalquilo C1-4 restringido, cada uno de los cuales puede estar sustituido en forma adicional con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, -S(O)2alquilo C1-4, OH, -C(O)-alquilo C1-4, oxo, CN, alquilo C1-6, alcoxi C1-4, cicloalquilo C3-7, -C(O)NH-alquilo C1-4, -C(O)N[alquil C1-4-alquilo C1-4], alquil C1-4-C(O)-, alquilsulfonilo C1-4-, -S(O)2NH-alquilo C1-4, y -S(O)2N[alquil C1-4-alquilo C1-4].
ARP110103426A 2010-09-20 2011-09-20 Compuestos de estructura de imidazotriazinona AR083058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38469410P 2010-09-20 2010-09-20

Publications (1)

Publication Number Publication Date
AR083058A1 true AR083058A1 (es) 2013-01-30

Family

ID=44720178

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103426A AR083058A1 (es) 2010-09-20 2011-09-20 Compuestos de estructura de imidazotriazinona

Country Status (17)

Country Link
US (3) US20120157458A1 (es)
EP (2) EP2619208B1 (es)
JP (2) JP5855109B2 (es)
CN (1) CN103313988B (es)
AR (1) AR083058A1 (es)
AU (2) AU2011305568B2 (es)
BR (1) BR112013008140A8 (es)
CA (1) CA2811714C (es)
DK (1) DK2619208T3 (es)
ES (1) ES2610360T3 (es)
HK (1) HK1187908A1 (es)
MX (1) MX2013003093A (es)
PL (1) PL2619208T3 (es)
RU (1) RU2603140C2 (es)
TW (1) TWI541244B (es)
UY (1) UY33616A (es)
WO (1) WO2012040230A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619208B1 (en) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
MX370433B (es) 2011-10-10 2019-12-13 H Lundbeck As Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014067962A1 (de) 2012-10-31 2014-05-08 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
US20180044343A1 (en) * 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) * 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
AU2017292650A1 (en) 2016-07-06 2018-12-13 H. Lundbeck A/S PDE9 inhibitors for treatment of peripheral diseases
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
CN109803653A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包括给予咪唑并吡嗪酮的组合治疗
DK3532064T3 (da) 2016-10-28 2020-08-24 H Lundbeck As Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
WO2018218104A1 (en) * 2017-05-26 2018-11-29 Imara, Inc. Methods of making and using pde9 inhibitors
EP3880256A4 (en) * 2018-11-14 2022-08-03 The Board of Trustees of the Leland Stanford Junior University TARGETING MAKAPP-PDE4D3 COMPLEXES IN NEURODEGENERATIVE DISEASES
KR20200068996A (ko) * 2018-12-06 2020-06-16 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
KR20220086607A (ko) * 2019-10-21 2022-06-23 에스케이바이오팜 주식회사 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
CN112724079A (zh) * 2021-02-04 2021-04-30 康化(上海)新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
EP1049695B1 (de) 1997-11-12 2002-02-13 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
IL161155A0 (en) * 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20060264624A1 (en) 2005-05-20 2006-11-23 Alexander Heim-Riether Methods for synthesizing imidazotriazinones
EP1896476A2 (en) 2005-06-28 2008-03-12 Orchid Research Laboratories Limited Novel pyrazolopyrimidinone derivatives
EP2152712B1 (en) * 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
EP2619208B1 (en) * 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN

Also Published As

Publication number Publication date
CN103313988B (zh) 2016-06-08
TWI541244B (zh) 2016-07-11
WO2012040230A1 (en) 2012-03-29
US20170152265A1 (en) 2017-06-01
RU2603140C2 (ru) 2016-11-20
JP2013540755A (ja) 2013-11-07
CA2811714A1 (en) 2012-03-29
AU2011305568B2 (en) 2015-12-10
AU2011305568A1 (en) 2013-04-04
TW201217381A (en) 2012-05-01
BR112013008140A2 (pt) 2017-12-05
AU2016200970A1 (en) 2016-03-03
BR112013008140A8 (pt) 2018-04-03
PL2619208T3 (pl) 2017-03-31
DK2619208T3 (en) 2017-01-30
JP5855109B2 (ja) 2016-02-09
CA2811714C (en) 2017-11-21
US20140330014A1 (en) 2014-11-06
RU2013118362A (ru) 2014-10-27
JP2016104747A (ja) 2016-06-09
EP2619208A1 (en) 2013-07-31
US9540380B2 (en) 2017-01-10
HK1187908A1 (zh) 2014-04-17
ES2610360T3 (es) 2017-04-27
CN103313988A (zh) 2013-09-18
MX2013003093A (es) 2013-10-28
EP3181566A1 (en) 2017-06-21
EP2619208B1 (en) 2016-11-09
UY33616A (es) 2012-04-30
US20120157458A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
PE20160200A1 (es) Inhibidores de bromodominios
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
PE20141059A1 (es) Indazoles
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR076794A1 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR088235A1 (es) Derivados de pirazoloquinolina
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
CO6210701A2 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
PE20190204A1 (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas

Legal Events

Date Code Title Description
FB Suspension of granting procedure